# Xencor Inc. (XNCR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $878M  
**Price:** $11.83 (-0.50%)

> Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb protein engineering platform, Xencor designs drug candidates optimized for enhanced efficacy and safety profiles to treat patients with cancer, asthma, allergic diseases, and autoimmune conditions. The company maintains a broad pipeline, with more than 20 programs in clinical testing and numerous others in preclinical development. Notably, three XmAb medicines are currently marketed by strategic partners, enabling milestone payments, royalties, and collaborative advancements. Xencor focuses on expanding the therapeutic potential of antibodies through innovative protein engineering from the ground up, addressing severe diseases where conventional treatments fall short. Founded in 1997 and headquartered in Monrovia, California, Xencor plays a key role in the biotechnology sector by advancing next-generation biologics for unmet medical needs.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $126M | — | -$178M | -$92M | — |
| 2024 | $110M | — | -$178M | -$233M | — |
| 2023 | $175M | — | -$132M | -$133M | — |
| 2022 | $165M | — | -$82M | -$55M | — |
| 2021 | $275M | — | $44M | $83M | — |
| 2020 | $123M | — | -$77M | -$69M | — |
| 2019 | $157M | — | $14M | $27M | — |
| 2018 | $41M | — | -$79M | -$70M | — |
| 2017 | $46M | — | -$43M | -$38M | — |
| 2016 | $109M | — | $44M | $45M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $875M | $240M | $636M | $54M | $76M |
| 2024 | $952M | $278M | $678M | $41M | $115M |
| 2023 | $965M | $303M | $662M | $54M | $162M |
| 2022 | $846M | $119M | $727M | $54M | — |
| 2021 | $838M | $105M | $734M | $143M | — |
| 2020 | $703M | $131M | $572M | $164M | — |
| 2019 | $670M | $77M | $593M | $50M | — |
| 2018 | $577M | $55M | $522M | $26M | — |
| 2017 | $390M | $74M | $316M | $17M | — |
| 2016 | $429M | $115M | $338M | $15M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$135M | $3M | -$138M |
| 2024 | -$202M | $6M | -$208M |
| 2023 | -$78M | $18M | -$96M |
| 2022 | $24M | $38M | -$14M |
| 2021 | -$17M | $13M | -$30M |
| 2020 | -$5M | $11M | -$16M |
| 2019 | $64M | $7M | $57M |
| 2018 | -$80M | $7M | -$87M |
| 2017 | -$34M | $5M | -$39M |
| 2016 | $95M | $2M | $94M |
| 2015 | $27M | $2M | $25M |

Source: [CompaniesByCap](https://companiesbycap.com/company/XNCR)